Areas of Focus

当前位置: > Technology > Areas of Focus

Areas of Focus

Bladder cancer and other genitourinary tumors

    Bladder Cancer (BC) ranks 11th in the most common malignant tumors, with nearly 549,000 new cases and over 199,000 death worldwide in 2018. The numbers of new BC patients and death in 2014 were 71,000 and 25,000 respectively in China. In recent years, the incidence has been increasing with an annual growth rate near 5%.

    Non-muscle invasive bladder cancer (NMIBC, tumors confined to the bladder mucosa and sub mucosa layers without invasion to the muscle layer) accounts for 70-80% of newly diagnosed bladder cancer patients.

    Currently, the common treatment of NMIBC is Trans-Urethral Resection of Bladder Tumor (TURBT). Because of high recurrence (60-70%) after TURBT surgery, intravesical chemotherapy or immunotherapy is usually required after the surgery. However, intravesical therapy is quite painful and chemotherapy may result in drug resistance. Therefore, there is an urgent need for drugs with novel mechanism and treatment regimen.

    In addition to bladder cancer, Asieris also focuses on the development of new drugs for other urogenital cancers, such as cervical cancer, ovarian cancer, prostate cancer, and renal carcinoma, etc.

Bladder cancer and other genitourinary tumors

Multi drug resistant infection

    Currently, the shortage of antibiotics against antimicrobial resistance (AMR) has become a common challenge worldwide. There has been limited success in the global efforts on the development of antibiotics with novel mechanism of action.

    Studies have shown that methionine amino peptidase (MetAP) is responsible for the cleavage of the initiator methionine from newly synthesized proteins.

    Knockout of MetAP1 enzyme gene in S. typhimurium and E. coli can lead to bacterial death or growth inhibition,

    Therefore, bacterial MetAP1 enzyme is a potential new target for anti-multidrug resistance (MDR) infection. Asieris Pharmaceuticals focuses on the development of bacterial MetAP1 enzyme inhibitors for combating MDR.


Multi drug resistant infection
返回顶部